Key clinical point: High prevalence of exocrine pancreatic insufficiency (EPI)-related fat malabsorption was observed in Asian Indian patients with type 2 diabetes mellitus (T2DM), which was significantly associated with autonomic dysfunction.

Major finding: EPI-related fat malabsorption (72 hours fecal fat > 18 g) was present in 44.9% and 6.1% of patients with and without T2DM, respectively (P < .05). Among patients with T2DM, those with or without EPI-related fat malabsorption had significantly higher proportion of parasympathetic nervous system (PNS) dysfunction (86.7% vs. 61.5%), sympathetic nervous system (SNS) dysfunction (92.4% vs. 72.3%), and PNS+SNS dysfunction (83.1 vs. 66.0%; all P < .05).

Study details: Findings are from a cross-sectional analysis of 118 patients with T2DM and 82 normoglycemic individuals.

Disclosures: This study was supported by the FLUID research grant of CMC, Vellore, India. The authors declared no conflict of interests.

Source: Anoop S et al. Diab Metab Syndr Clin Res Rev. 2021 Sep 4. doi: 10.1016/j.dsx.2021.102273.

Key clinical point: High prevalence of exocrine pancreatic insufficiency (EPI)-related fat malabsorption was observed in Asian Indian patients with type 2 diabetes mellitus (T2DM), which was significantly associated with autonomic dysfunction.

Major finding: EPI-related fat malabsorption (72 hours fecal fat > 18 g) was present in 44.9% and 6.1% of patients with and without T2DM, respectively (P < .05). Among patients with T2DM, those with or without EPI-related fat malabsorption had significantly higher proportion of parasympathetic nervous system (PNS) dysfunction (86.7% vs. 61.5%), sympathetic nervous system (SNS) dysfunction (92.4% vs. 72.3%), and PNS+SNS dysfunction (83.1 vs. 66.0%; all P < .05).

Study details: Findings are from a cross-sectional analysis of 118 patients with T2DM and 82 normoglycemic individuals.

Disclosures: This study was supported by the FLUID research grant of CMC, Vellore, India. The authors declared no conflict of interests.

Source: Anoop S et al. Diab Metab Syndr Clin Res Rev. 2021 Sep 4. doi: 10.1016/j.dsx.2021.102273.

Key clinical point: High prevalence of exocrine pancreatic insufficiency (EPI)-related fat malabsorption was observed in Asian Indian patients with type 2 diabetes mellitus (T2DM), which was significantly associated with autonomic dysfunction.

Major finding: EPI-related fat malabsorption (72 hours fecal fat > 18 g) was present in 44.9% and 6.1% of patients with and without T2DM, respectively (P < .05). Among patients with T2DM, those with or without EPI-related fat malabsorption had significantly higher proportion of parasympathetic nervous system (PNS) dysfunction (86.7% vs. 61.5%), sympathetic nervous system (SNS) dysfunction (92.4% vs. 72.3%), and PNS+SNS dysfunction (83.1 vs. 66.0%; all P < .05).

Study details: Findings are from a cross-sectional analysis of 118 patients with T2DM and 82 normoglycemic individuals.

Disclosures: This study was supported by the FLUID research grant of CMC, Vellore, India. The authors declared no conflict of interests.

Source: Anoop S et al. Diab Metab Syndr Clin Res Rev. 2021 Sep 4. doi: 10.1016/j.dsx.2021.102273.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI;

Key clinical point: Presence of insulin resistance did not change the fecal elastase-1 (FE-1) levels or the rate of exocrine pancreatic insufficiency (EPI) in patients with obesity.

Major finding: Mean FE-1 levels (430.27 ± 207.63 vs. 508.64 ± 188.77; P = .119) and the rate of EPI (FE-1 < 200 mg/g; 25.7% vs. 10.0%; P = .104) were not significantly different in patients with or without insulin resistance.

Study details: Findings are from a retrospective analysis of 65 patients with obesity (body mass index, >30 kg/m²) with (n=35) or without (n=30) insulin resistance.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Uysal BB et al. Med Sci. 2021 Aug 23. doi: 10.5455/medscience.2021.05.164.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI;

Key clinical point: Presence of insulin resistance did not change the fecal elastase-1 (FE-1) levels or the rate of exocrine pancreatic insufficiency (EPI) in patients with obesity.

Major finding: Mean FE-1 levels (430.27 ± 207.63 vs. 508.64 ± 188.77; P = .119) and the rate of EPI (FE-1 < 200 mg/g; 25.7% vs. 10.0%; P = .104) were not significantly different in patients with or without insulin resistance.

Study details: Findings are from a retrospective analysis of 65 patients with obesity (body mass index, >30 kg/m²) with (n=35) or without (n=30) insulin resistance.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Uysal BB et al. Med Sci. 2021 Aug 23. doi: 10.5455/medscience.2021.05.164.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI;

Key clinical point: Presence of insulin resistance did not change the fecal elastase-1 (FE-1) levels or the rate of exocrine pancreatic insufficiency (EPI) in patients with obesity.

Major finding: Mean FE-1 levels (430.27 ± 207.63 vs. 508.64 ± 188.77; P = .119) and the rate of EPI (FE-1 < 200 mg/g; 25.7% vs. 10.0%; P = .104) were not significantly different in patients with or without insulin resistance.

Study details: Findings are from a retrospective analysis of 65 patients with obesity (body mass index, >30 kg/m²) with (n=35) or without (n=30) insulin resistance.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Uysal BB et al. Med Sci. 2021 Aug 23. doi: 10.5455/medscience.2021.05.164.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI; fecal elastase < 200 mg/g). Findings highlight the usefulness of metabolic studies to identify novel biomarkers for EPI diagnosis in CP.

Major finding: A 6-metabolite panel including arginine-proline-threonine tripeptide, 1 phosphatidylcholine, pentasine, and 3 phosphatidylserines was effective in discriminating between the presence and absence of EPI in patients with CP (area under the receiver operator characteristic curve, 0.79; 95% CI 0.62-0.92).

Study details: This metabolic study included 53 patients with CP with (60.4%) or without (39.6%) EPI.

Disclosures: This study was funded by grants from the Junta de Andalucia and the Instituto de Salud Carlos III. The authors declared no conflict of interests.

Source: Díaz C et al. Medicina. 2021 Aug 26. doi: 10.3390/medicina57090876.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI; fecal elastase < 200 mg/g). Findings highlight the usefulness of metabolic studies to identify novel biomarkers for EPI diagnosis in CP.

Major finding: A 6-metabolite panel including arginine-proline-threonine tripeptide, 1 phosphatidylcholine, pentasine, and 3 phosphatidylserines was effective in discriminating between the presence and absence of EPI in patients with CP (area under the receiver operator characteristic curve, 0.79; 95% CI 0.62-0.92).

Study details: This metabolic study included 53 patients with CP with (60.4%) or without (39.6%) EPI.

Disclosures: This study was funded by grants from the Junta de Andalucia and the Instituto de Salud Carlos III. The authors declared no conflict of interests.

Source: Díaz C et al. Medicina. 2021 Aug 26. doi: 10.3390/medicina57090876.

Key clinical point: Blood specimens from patients with chronic pancreatitis (CP) yielded a panel of 6 metabolites that showed differential expression with the presence or absence of exocrine pancreatic insufficiency (EPI; fecal elastase < 200 mg/g). Findings highlight the usefulness of metabolic studies to identify novel biomarkers for EPI diagnosis in CP.

Major finding: A 6-metabolite panel including arginine-proline-threonine tripeptide, 1 phosphatidylcholine, pentasine, and 3 phosphatidylserines was effective in discriminating between the presence and absence of EPI in patients with CP (area under the receiver operator characteristic curve, 0.79; 95% CI 0.62-0.92).

Study details: This metabolic study included 53 patients with CP with (60.4%) or without (39.6%) EPI.

Disclosures: This study was funded by grants from the Junta de Andalucia and the Instituto de Salud Carlos III. The authors declared no conflict of interests.

Source: Díaz C et al. Medicina. 2021 Aug 26. doi: 10.3390/medicina57090876.

Key clinical point: Prevalence of positive anti-SARS-CoV-2 antibodies was similar in chronic myeloid leukemia (CML) population and general populations in Italy and was not associated with the type of tyrosine kinase inhibitor (TKI) therapy or treatment-free remission (TFR) status, thereby reassuring the safe continuation of TKI treatment in patients with CML during the COVID-19 pandemic.

Major finding: The prevalence of SARS-CoV-2 infection was comparable in CML (1.95%; 95% CI 1.09-3.46) and general (2.5%) populations in Italy. Positive anti-SARS-CoV-2 serological test was not associated with the type of TKI treatment (P = .19) or TFR status (P = .40).

Study details: Findings are from a cross-sectional study including 564 adult patients with CML tested for anti-SARS-CoV-2 immunoglobulin (Ig)M and/or IgG antibodies.

Disclosures: This study was supported by Fondazione Cariverona (ENACT Project). The authors declared no conflict of interests.

Source: Bonifacio M et al. Cancer Med. 2021 Aug 31. doi: 10.1002/cam4.4179.

Key clinical point: Prevalence of positive anti-SARS-CoV-2 antibodies was similar in chronic myeloid leukemia (CML) population and general populations in Italy and was not associated with the type of tyrosine kinase inhibitor (TKI) therapy or treatment-free remission (TFR) status, thereby reassuring the safe continuation of TKI treatment in patients with CML during the COVID-19 pandemic.

Major finding: The prevalence of SARS-CoV-2 infection was comparable in CML (1.95%; 95% CI 1.09-3.46) and general (2.5%) populations in Italy. Positive anti-SARS-CoV-2 serological test was not associated with the type of TKI treatment (P = .19) or TFR status (P = .40).

Study details: Findings are from a cross-sectional study including 564 adult patients with CML tested for anti-SARS-CoV-2 immunoglobulin (Ig)M and/or IgG antibodies.

Disclosures: This study was supported by Fondazione Cariverona (ENACT Project). The authors declared no conflict of interests.

Source: Bonifacio M et al. Cancer Med. 2021 Aug 31. doi: 10.1002/cam4.4179.

Key clinical point: Prevalence of positive anti-SARS-CoV-2 antibodies was similar in chronic myeloid leukemia (CML) population and general populations in Italy and was not associated with the type of tyrosine kinase inhibitor (TKI) therapy or treatment-free remission (TFR) status, thereby reassuring the safe continuation of TKI treatment in patients with CML during the COVID-19 pandemic.

Major finding: The prevalence of SARS-CoV-2 infection was comparable in CML (1.95%; 95% CI 1.09-3.46) and general (2.5%) populations in Italy. Positive anti-SARS-CoV-2 serological test was not associated with the type of TKI treatment (P = .19) or TFR status (P = .40).

Study details: Findings are from a cross-sectional study including 564 adult patients with CML tested for anti-SARS-CoV-2 immunoglobulin (Ig)M and/or IgG antibodies.

Disclosures: This study was supported by Fondazione Cariverona (ENACT Project). The authors declared no conflict of interests.

Source: Bonifacio M et al. Cancer Med. 2021 Aug 31. doi: 10.1002/cam4.4179.

Key clinical point: Imatinib discontinuation was feasible without affecting clinical outcomes in pediatric patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with frontline imatinib with a sustained deep molecular response (DMR) for at least 2 years with imatinib.

Major finding: The molecular-free remission rate at 6, 12, and 36 months was 61%, 56%, and 56%, respectively. Of the 7 children who had a molecular relapse, 6 regained molecular response (MR) 4 and 1 patient achieved major MR after restarting imatinib. No deaths or disease progression were reported.

Study details: Findings are from a retrospective analysis of 18 children with CML-CP from the International Registry of Childhood CML who were treated with frontline imatinib and had sustained MR4 for at least 2 years before imatinib discontinuation to attempt treatment-free remission.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Millot F et al. Cancers. 2021 Aug 15. doi: 10.3390/cancers13164102.

Key clinical point: Imatinib discontinuation was feasible without affecting clinical outcomes in pediatric patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with frontline imatinib with a sustained deep molecular response (DMR) for at least 2 years with imatinib.

Major finding: The molecular-free remission rate at 6, 12, and 36 months was 61%, 56%, and 56%, respectively. Of the 7 children who had a molecular relapse, 6 regained molecular response (MR) 4 and 1 patient achieved major MR after restarting imatinib. No deaths or disease progression were reported.

Study details: Findings are from a retrospective analysis of 18 children with CML-CP from the International Registry of Childhood CML who were treated with frontline imatinib and had sustained MR4 for at least 2 years before imatinib discontinuation to attempt treatment-free remission.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Millot F et al. Cancers. 2021 Aug 15. doi: 10.3390/cancers13164102.

Key clinical point: Imatinib discontinuation was feasible without affecting clinical outcomes in pediatric patients with chronic-phase chronic myeloid leukemia (CML-CP) treated with frontline imatinib with a sustained deep molecular response (DMR) for at least 2 years with imatinib.

Major finding: The molecular-free remission rate at 6, 12, and 36 months was 61%, 56%, and 56%, respectively. Of the 7 children who had a molecular relapse, 6 regained molecular response (MR) 4 and 1 patient achieved major MR after restarting imatinib. No deaths or disease progression were reported.

Study details: Findings are from a retrospective analysis of 18 children with CML-CP from the International Registry of Childhood CML who were treated with frontline imatinib and had sustained MR4 for at least 2 years before imatinib discontinuation to attempt treatment-free remission.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Millot F et al. Cancers. 2021 Aug 15. doi: 10.3390/cancers13164102.

Key clinical point: Improvements in patient-reported functional outcomes in patients with chronic-phase chronic myeloid leukemia (CML-CP) in treatment-free remission (TFR) deteriorated after restarting tyrosine kinase inhibitor (TKI).

Major finding: Among patients in TFR at 12 months, 92.0% had at least a 3-point improvement in social function, 71.4% in social isolation, 9.8% in sexual satisfaction, and 3.6% in physical function. No patients had at least a 3-point improvement in cognitive function or interest in sexual activity. All functional changes worsened after restarting TKI.

Study details: Findings are from the prospective LAST study including 172 adult patients with CML-CP attempting TFR after at least 3 years of treatment with a first- or second-generation TKI and at least 2 years in molecular response 4.

Disclosures: This study was supported by the National Cancer Institute at the National Institute of Health. The lead author reported research support from the American Society of Hematology. Some investigators reported ties with various pharmaceutical companies.

Source: Schoenbeck KL et al. J Natl Cancer Inst. 2021 Sep 7. doi: 10.1093/jnci/djab184.

Key clinical point: Improvements in patient-reported functional outcomes in patients with chronic-phase chronic myeloid leukemia (CML-CP) in treatment-free remission (TFR) deteriorated after restarting tyrosine kinase inhibitor (TKI).

Major finding: Among patients in TFR at 12 months, 92.0% had at least a 3-point improvement in social function, 71.4% in social isolation, 9.8% in sexual satisfaction, and 3.6% in physical function. No patients had at least a 3-point improvement in cognitive function or interest in sexual activity. All functional changes worsened after restarting TKI.

Study details: Findings are from the prospective LAST study including 172 adult patients with CML-CP attempting TFR after at least 3 years of treatment with a first- or second-generation TKI and at least 2 years in molecular response 4.

Disclosures: This study was supported by the National Cancer Institute at the National Institute of Health. The lead author reported research support from the American Society of Hematology. Some investigators reported ties with various pharmaceutical companies.

Source: Schoenbeck KL et al. J Natl Cancer Inst. 2021 Sep 7. doi: 10.1093/jnci/djab184.

Key clinical point: Improvements in patient-reported functional outcomes in patients with chronic-phase chronic myeloid leukemia (CML-CP) in treatment-free remission (TFR) deteriorated after restarting tyrosine kinase inhibitor (TKI).

Major finding: Among patients in TFR at 12 months, 92.0% had at least a 3-point improvement in social function, 71.4% in social isolation, 9.8% in sexual satisfaction, and 3.6% in physical function. No patients had at least a 3-point improvement in cognitive function or interest in sexual activity. All functional changes worsened after restarting TKI.

Study details: Findings are from the prospective LAST study including 172 adult patients with CML-CP attempting TFR after at least 3 years of treatment with a first- or second-generation TKI and at least 2 years in molecular response 4.

Disclosures: This study was supported by the National Cancer Institute at the National Institute of Health. The lead author reported research support from the American Society of Hematology. Some investigators reported ties with various pharmaceutical companies.

Source: Schoenbeck KL et al. J Natl Cancer Inst. 2021 Sep 7. doi: 10.1093/jnci/djab184.

Key clinical point: BCR-ABL1 transcript doubling time (DT) at 2 months was strongly associated with treatment-free remission (TFR) failure after imatinib discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: The molecular recurrence-free survival at 12 months was 5.0% in patients in the high-risk (DT at 2 months, <12.75 days) vs. 47.2% in the intermediate-risk (DT at 2 months, ≥12.75 days) and 90.1% in the low-risk (DT at 2 months, 0 or less) groups (P < .001). DT at 2 months determined high-risk (hazard ratio [HR] 8.062; P = .0006) and low-risk (HR 0.196; P = .0110) groups for TFR failure.

Study details: This study assessed 131 patients with CML-CP in the imatinib discontinuation phase enrolled in the TRAD study.

Disclosures: This study was supported by BMS Canada and partly by the Princess Margaret Cancer Foundation. The lead author reported a research grant from the BMS and Novartis.

Source: Kim DDH et al. Br J Haematol. 2021 Sep 8. doi: 10.1111/bjh.17807

Key clinical point: BCR-ABL1 transcript doubling time (DT) at 2 months was strongly associated with treatment-free remission (TFR) failure after imatinib discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: The molecular recurrence-free survival at 12 months was 5.0% in patients in the high-risk (DT at 2 months, <12.75 days) vs. 47.2% in the intermediate-risk (DT at 2 months, ≥12.75 days) and 90.1% in the low-risk (DT at 2 months, 0 or less) groups (P < .001). DT at 2 months determined high-risk (hazard ratio [HR] 8.062; P = .0006) and low-risk (HR 0.196; P = .0110) groups for TFR failure.

Study details: This study assessed 131 patients with CML-CP in the imatinib discontinuation phase enrolled in the TRAD study.

Disclosures: This study was supported by BMS Canada and partly by the Princess Margaret Cancer Foundation. The lead author reported a research grant from the BMS and Novartis.

Source: Kim DDH et al. Br J Haematol. 2021 Sep 8. doi: 10.1111/bjh.17807

Key clinical point: BCR-ABL1 transcript doubling time (DT) at 2 months was strongly associated with treatment-free remission (TFR) failure after imatinib discontinuation in patients with chronic-phase chronic myeloid leukemia (CML-CP).

Major finding: The molecular recurrence-free survival at 12 months was 5.0% in patients in the high-risk (DT at 2 months, <12.75 days) vs. 47.2% in the intermediate-risk (DT at 2 months, ≥12.75 days) and 90.1% in the low-risk (DT at 2 months, 0 or less) groups (P < .001). DT at 2 months determined high-risk (hazard ratio [HR] 8.062; P = .0006) and low-risk (HR 0.196; P = .0110) groups for TFR failure.

Study details: This study assessed 131 patients with CML-CP in the imatinib discontinuation phase enrolled in the TRAD study.

Disclosures: This study was supported by BMS Canada and partly by the Princess Margaret Cancer Foundation. The lead author reported a research grant from the BMS and Novartis.

Source: Kim DDH et al. Br J Haematol. 2021 Sep 8. doi: 10.1111/bjh.17807

Key clinical point: Asciminib showed superior efficacy and a favorable safety profile compared with bosutinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant or intolerant to at least 2 prior tyrosine kinase inhibitor (TKI) therapies.

Major finding: The rates of major molecular response (MMR) at week 24 in patients receiving asciminib and bosutinib were 25.5% and 13.2%, respectively (difference 12.2%; P = .029). Bosutinib vs. asciminib arms had a more frequent occurrence of grade 3 or higher adverse events (AEs; 60.5% vs. 50.6%) and AEs leading to treatment discontinuation (21.1% vs. 5.8%).

Study details: Findings are from the phase 3 ASCEMBL trial including 233 adult patients with CML-CP previously treated with at least 2 TKIs randomly assigned to receive either 40 mg asciminib twice daily or 500 mg bosutinib once daily.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including, the lead author, reported ties with various pharmaceutical companies, including Novartis.

Source: Rea D et al. Blood. 2021 Aug 18. doi: 10.1182/blood.2020009984.

Key clinical point: Asciminib showed superior efficacy and a favorable safety profile compared with bosutinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant or intolerant to at least 2 prior tyrosine kinase inhibitor (TKI) therapies.

Major finding: The rates of major molecular response (MMR) at week 24 in patients receiving asciminib and bosutinib were 25.5% and 13.2%, respectively (difference 12.2%; P = .029). Bosutinib vs. asciminib arms had a more frequent occurrence of grade 3 or higher adverse events (AEs; 60.5% vs. 50.6%) and AEs leading to treatment discontinuation (21.1% vs. 5.8%).

Study details: Findings are from the phase 3 ASCEMBL trial including 233 adult patients with CML-CP previously treated with at least 2 TKIs randomly assigned to receive either 40 mg asciminib twice daily or 500 mg bosutinib once daily.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including, the lead author, reported ties with various pharmaceutical companies, including Novartis.

Source: Rea D et al. Blood. 2021 Aug 18. doi: 10.1182/blood.2020009984.

Key clinical point: Asciminib showed superior efficacy and a favorable safety profile compared with bosutinib in patients with chronic-phase chronic myeloid leukemia (CML-CP) resistant or intolerant to at least 2 prior tyrosine kinase inhibitor (TKI) therapies.

Major finding: The rates of major molecular response (MMR) at week 24 in patients receiving asciminib and bosutinib were 25.5% and 13.2%, respectively (difference 12.2%; P = .029). Bosutinib vs. asciminib arms had a more frequent occurrence of grade 3 or higher adverse events (AEs; 60.5% vs. 50.6%) and AEs leading to treatment discontinuation (21.1% vs. 5.8%).

Study details: Findings are from the phase 3 ASCEMBL trial including 233 adult patients with CML-CP previously treated with at least 2 TKIs randomly assigned to receive either 40 mg asciminib twice daily or 500 mg bosutinib once daily.

Disclosures: This study was sponsored and funded by Novartis Pharmaceuticals Corporation. Some investigators including, the lead author, reported ties with various pharmaceutical companies, including Novartis.

Source: Rea D et al. Blood. 2021 Aug 18. doi: 10.1182/blood.2020009984.

Key clinical point: In patients with chronic-phase chronic myeloid leukemia (CML-CP) undergoing tyrosine kinase inhibitor (TKI) treatment, the European Treatment and Outcome Study for CML long-term survival (ELTS) offered better overall prediction accuracy than the Sokal score, especially in those receiving the second-generation TKI (2G-TKIs).

Major finding: Overall, ELTS was a better predictor of molecular response (MR)4 (high vs. low; hazard ratio [HR], 0.6; P = .013), MR4.5 (high vs. low; HR, 0.6; P = .030), and CML-related survival (high vs. low; HR, 4.3; P < .001) than the Sokal score. In patients receiving 2G-TKIs, only the ELTS score predicted complete cytogenic response, major MR, MR4, and failure- and progression-free survival (all P < .05).

Study details: Findings are from a retrospective analysis of 1,661 adult patients with newly

diagnosed CML-CP receiving either imatinib, dasatinib, or nilotinib.

Disclosures: This study was partly funded by the National Nature Science Foundation of China. RP

Gale reported ties with various pharmaceutical companies. Other authors had no disclosures.

Source: Zhang XS et al. Leukemia. 2021 Aug 19. doi: 10.1038/s41375-021-01387-y.

Key clinical point: In patients with chronic-phase chronic myeloid leukemia (CML-CP) undergoing tyrosine kinase inhibitor (TKI) treatment, the European Treatment and Outcome Study for CML long-term survival (ELTS) offered better overall prediction accuracy than the Sokal score, especially in those receiving the second-generation TKI (2G-TKIs).

Major finding: Overall, ELTS was a better predictor of molecular response (MR)4 (high vs. low; hazard ratio [HR], 0.6; P = .013), MR4.5 (high vs. low; HR, 0.6; P = .030), and CML-related survival (high vs. low; HR, 4.3; P < .001) than the Sokal score. In patients receiving 2G-TKIs, only the ELTS score predicted complete cytogenic response, major MR, MR4, and failure- and progression-free survival (all P < .05).

Study details: Findings are from a retrospective analysis of 1,661 adult patients with newly

diagnosed CML-CP receiving either imatinib, dasatinib, or nilotinib.

Disclosures: This study was partly funded by the National Nature Science Foundation of China. RP

Gale reported ties with various pharmaceutical companies. Other authors had no disclosures.

Source: Zhang XS et al. Leukemia. 2021 Aug 19. doi: 10.1038/s41375-021-01387-y.

Key clinical point: In patients with chronic-phase chronic myeloid leukemia (CML-CP) undergoing tyrosine kinase inhibitor (TKI) treatment, the European Treatment and Outcome Study for CML long-term survival (ELTS) offered better overall prediction accuracy than the Sokal score, especially in those receiving the second-generation TKI (2G-TKIs).

Major finding: Overall, ELTS was a better predictor of molecular response (MR)4 (high vs. low; hazard ratio [HR], 0.6; P = .013), MR4.5 (high vs. low; HR, 0.6; P = .030), and CML-related survival (high vs. low; HR, 4.3; P < .001) than the Sokal score. In patients receiving 2G-TKIs, only the ELTS score predicted complete cytogenic response, major MR, MR4, and failure- and progression-free survival (all P < .05).

Study details: Findings are from a retrospective analysis of 1,661 adult patients with newly

diagnosed CML-CP receiving either imatinib, dasatinib, or nilotinib.

Disclosures: This study was partly funded by the National Nature Science Foundation of China. RP

Gale reported ties with various pharmaceutical companies. Other authors had no disclosures.

Source: Zhang XS et al. Leukemia. 2021 Aug 19. doi: 10.1038/s41375-021-01387-y.

Key clinical point: Pulmonary hypertension (PH) is common in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI), warranting careful screening for PH in this patient population.

Major finding: Overall, 10.7% of patients undergoing transthoracic echocardiography (TTE) during TKI treatment were diagnosed with PH. Dasatinib treatment (odds ratio [OR] 8.2; P = .03), age above 60 years (OR 12.3; P = .04), and presence of cardiopulmonary symptoms/signs (OR 36.1; P = .001) were significant risk factors for PH.

Study details: Findings are from a retrospective analysis of 112 patients with CML who underwent TTE during TKI treatment.

Disclosures: This study was funded by the Research Fund of Chungnam National University Hospital and the Bio and Medical Technology Development Program of the National Research Foundation of Korea. The authors declared no conflict of interests.

Source: Song IC et al. Medicine. 2021 Aug 20. doi: 10.1097/MD.0000000000026975.

Key clinical point: Pulmonary hypertension (PH) is common in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI), warranting careful screening for PH in this patient population.

Major finding: Overall, 10.7% of patients undergoing transthoracic echocardiography (TTE) during TKI treatment were diagnosed with PH. Dasatinib treatment (odds ratio [OR] 8.2; P = .03), age above 60 years (OR 12.3; P = .04), and presence of cardiopulmonary symptoms/signs (OR 36.1; P = .001) were significant risk factors for PH.

Study details: Findings are from a retrospective analysis of 112 patients with CML who underwent TTE during TKI treatment.

Disclosures: This study was funded by the Research Fund of Chungnam National University Hospital and the Bio and Medical Technology Development Program of the National Research Foundation of Korea. The authors declared no conflict of interests.

Source: Song IC et al. Medicine. 2021 Aug 20. doi: 10.1097/MD.0000000000026975.

Key clinical point: Pulmonary hypertension (PH) is common in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKI), warranting careful screening for PH in this patient population.

Major finding: Overall, 10.7% of patients undergoing transthoracic echocardiography (TTE) during TKI treatment were diagnosed with PH. Dasatinib treatment (odds ratio [OR] 8.2; P = .03), age above 60 years (OR 12.3; P = .04), and presence of cardiopulmonary symptoms/signs (OR 36.1; P = .001) were significant risk factors for PH.

Study details: Findings are from a retrospective analysis of 112 patients with CML who underwent TTE during TKI treatment.

Disclosures: This study was funded by the Research Fund of Chungnam National University Hospital and the Bio and Medical Technology Development Program of the National Research Foundation of Korea. The authors declared no conflict of interests.

Source: Song IC et al. Medicine. 2021 Aug 20. doi: 10.1097/MD.0000000000026975.